Net earnings were $60 million or $0.93 per fully diluted share. Adjusted net earnings were $49.5 million, or $0.77 per fully diluted share.
Recent Business Developments
-- Declared, in July, a $0.16 per share quarterly cash dividend, a $0.01
or 6.7% increase. This is the company's 73rd consecutive quarterly
-- Re-purchased approximately 279,000 shares of Beckman Coulter stock at
an average price of $69.55 per share.
-- Signed a new agreement with Premier, Inc., the largest healthcare
alliance in the United States, for Beckman Coulter's offering of flow
cytometry instruments along with its core laboratory systems and
-- Signed agreements with Amerinet, Inc., one of the nation's largest
healthcare group purchasing organizations, to provide a full range of
core laboratory systems and supplies.
-- Signed agreements with Johns Hopkins University, a leader in cancer
genomics research, that provide Beckman Coulter exclusive options to
license cancer genomics intellectual property that may arise from its
studies of multiple types of cancer including breast, colon and six
First Nine Months Summary
Through the first nine months of 2007, revenue increased 8.6%, or 6.8%
in constant currency, over the prior year period. The acquisition of
Lumigen contributed about 1% to this growth. Year-to-date 2007 consumables
growth was 10.5%, or 8.8% in constant currency. The Lumigen contribution to
consumables growth was 1.6%. Gross margin was 46.9% compared to 47.6%
(adjusted) for the first nine months of 2006. Operating income increased by
22% and pretax profit increased by 74%; adjusting for special items,
operating income increased by 10.1% and pretax profit increased by 12.9%.
|SOURCE Beckman Coulter, Inc.|
Copyright©2007 PR Newswire.
All rights reserved